Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02060370 · ClinicalTrials.gov registry record · Phase 2
Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
A Phase 2 study of Kidney Cancer and Genitourinary Cancer, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 5
- Study locations
NCT02060370 is a Phase 2 study of Kidney Cancer and Genitourinary Cancer that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 60 participants, below the 879-participant average among 60 other Kidney Cancer trials with a reported enrollment target (93% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT02060370, a Phase 2 study of Kidney Cancer and Genitourinary Cancer, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 5
- Study locations
Study Summary
The goal of this clinical research study is to learn more about the safety of giving sunitinib to patients with metastatic kidney cancer for 2 weeks followed by 1 week in which they receive no drug. Researchers want to learn more about the side effects of the drug and the effects of a different dosing schedule.
Conditions Studied
Interventions
- DRUG Sunitinib
- BEHAVIORAL Questionnaire
Study Locations (5)
California
- Stanford University Medical Center - Stanford
North Carolina
- Lineberger Cancer Center - Chapel Hill
Ohio
- Cleveland Clinic Taussig Cancer Institute - Cleveland
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2014-08 |
| Est. Completion | 2019-01-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02060370
The ClinicalTrials.gov registry entry for NCT02060370 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 879-participant average among 60 other Kidney Cancer trials with a reported enrollment target (93% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Kidney Cancer appearing as the primary indexed condition, and to 2 interventions - of which Sunitinib is the first listed.
NCT02060370 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, North Carolina, Ohio.
Frequently Asked Questions
What is clinical trial NCT02060370 about?
NCT02060370 is a clinical study titled "Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)". The goal of this clinical research study is to learn more about the safety of giving sunitinib to patients with metastatic kidney cancer for 2 weeks followed by 1 week in which they receive no drug. Researchers want to learn more about the side effects of the drug and the effects of a different dosi...
What is the current status of trial NCT02060370?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2014-08. Estimated completion is 2019-01-02.
What conditions does trial NCT02060370 study?
This clinical trial studies the following conditions: Kidney Cancer, Genitourinary Cancer.
What interventions are being tested in trial NCT02060370?
The interventions under investigation include: Sunitinib (DRUG), Questionnaire (BEHAVIORAL).
Who is sponsoring clinical trial NCT02060370?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02060370 being conducted?
This trial has 5 study locations across California, North Carolina, Ohio, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
RECRUITING · Phase 2
-
NSAID Use After Robotic Partial Nephrectomy
RECRUITING · Phase 2
-
Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus
RECRUITING · Phase 2
-
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
RECRUITING · Phase 2
-
CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition
RECRUITING · Phase 2
-
Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.